Skeletal muscle terminal differentiation is characterized by the fusion of myoblasts to multinucleated myotubes, musclespecific gene activation, and terminal withdrawal from the cell cycle (18, 24, 38) . Terminal differentiation in cultured myoblasts requires serum deprivation in addition to the expression of the myogenic basic helix-loop-helix (bHLH) factors. For example, C2C12 myoblasts express the bHLH factor MyoD and are committed to the myogenic lineage, but they are prevented from cell cycle withdrawal and phenotypic differentiation by a high concentration of mitogens in the medium. Mitogens appear to block terminal differentiation by promoting the expression of Id, a dominant-negative HLH factor that inhibits the actions of the myogenic bHLH factors (1) . It has also been proposed that mitogen-activated protein kinase C directly phosphorylates and thereby inactivates the myogenic bHLH factors (19) . Once myotubes have formed, however, cells become unresponsive to further mitogen stimulation and are unable to reenter the cell cycle (17, 21, 34) ; however, cultures of myotubes prepared from Rb-deficient mice are capable of low levels of DNA synthesis (29) . Maintenance of terminal cell cycle arrest under conditions of mitogen stimulation remains a topic about which little is known.
Previous studies with mammalian and yeast systems demonstrated that a family of cyclin-dependent kinases (cdk's) are key regulators of cell cycle progression (23, 30) . The activities of these protein kinases are dependent on their association with different subsets of cyclin subunits whose expression oscillates during the cell cycle. The cdk inhibitors represent a new class of cell cycle regulators that bind to the cdk or the cyclincdk complex. To date, molecular clones for at least five cdk inhibitors have been isolated: p15, p16, p18, p21, and p27 (7, 11, 26) . These proteins function as negative regulators of cell proliferation by virtue of their ability to inhibit the activity of cyclin kinases. The inhibition of cdk's will result in the hypophosphorylation of the retinoblastoma protein with subsequent sequestration of the E2F transcription factor, which is required for the activation of S-phase genes. The cdk inhibitors fall into two general classes on the basis of sequence homology: p15, p16, and p18, which are specific for cdk4 and cdk6; and p21 and p27, which have a broad specificity for cdk's. In addition, the cdk inhibitor p21 (also named SDI1, WAF1, CIP1, and CAP20) can also function as a direct inhibitor of DNA polymerase by binding to the PCNA subunit (35) . Direct transcriptional activation of p21 by the p53 tumor suppressor has also been demonstrated (6) , and this induction has been correlated with radiation-induced cell cycle arrest in fibroblasts (4) . Since the expression of these factors can be regulated at the level of transcription, the cdk inhibitors represent potential targets for myogenic growth-regulatory transcription factors. However, the role of the cdk inhibitors in terminally differentiating myocytes is unknown.
We have investigated p21 cdk inhibitor regulation upon skeletal myogenesis. This factor is dramatically upregulated at the levels of mRNA, protein, and activity during skeletal myocyte terminal differentiation, and it occurs in a complex with cdk's in myotubes. Furthermore, its expression is sustained in myotubes that are reexposed to high concentrations of mitogens. These data indicate that the upregulation and sustained expression of p21 are important features of terminal cell cycle arrest during myocyte differentiation.
MATERIALS AND METHODS
Cell culture and immunostaining. C2C12 myoblasts were kept in growth medium (Dulbecco modified Eagle medium [DMEM] , 20% fetal bovine serum [FBS] ). To prepare differentiated myotubes, myoblasts were exposed to differ-entiation medium (DMEM, 2% heat-inactivated horse serum) for 48 h and then exposed to 10 M cytosine ␤-D-arabinofuranoside (ara-cytosine) for 48 h to eliminate replicating, nondifferentiated myoblasts. The resulting cultures typically displayed Ͼ95% of the nuclei to be present in multinucleated cells by visual examination. 10T1/2-MyoD cells were prepared by infecting 10T1/2 cells (clone 8) (28) with a retroviral vector encoding MyoD and the neomycin resistance gene (39) . Two days after infection, the cells were selected in medium containing G418 (0.6 mg/ml; GIBCO BRL), and G418-resistant cells were isolated by using cloning rings. Clonal cell lines were maintained in 20% FBS in DMEM containing G418 (0.3 mg/ml). A MyoD-transformed clone, termed 10T1/2-MyoD, was used in this study. These cells efficiently formed multinucleated myotubes when exposed to differentiation medium. For immunostaining, the cells were fixed with HistoChoice MB (Amresco), permeabilized for 5 min with 0.5% Nonidet P-40 (NP-40)-phosphate-buffered saline (PBS) and blocked for 15 min with normal goat serum. The cells were incubated with anti-myosin heavy-chain monoclonal antibody (MF20), using the HistoMark streptavidin-horseradish peroxidase system (Kirkegaard & Perry Laboratories). Peroxidase activity was developed with diaminobenzidine substrate (Kirkegaard & Perry Laboratories). The cells were counterstained with hematoxylin-eosin, mounted with Permount (Fisher), and visualized with an Olympus AH-2 microscope.
Immunoblotting. Cells were lysed by rocking at 4ЊC in NP-40 lysis buffer (50 mM Tris [pH 8.0], 150 mM NaCl, 5 mM EDTA, 0.5% NP-40). The cell lysates were cleared of insoluble materials by centrifugation at 12,000 ϫ g for 10 min. For coupled immunoprecipitation-immunoblotting, 500 g of each lysate was precleaned with protein A-agarose and then incubated with 1 g of either anti-cdk2 (Santa Cruz Biotechnology), anti-cdk4 (Santa Cruz Biotechnology), or anti-p21 (Pharmingen or Santa Cruz Biotechnology) antibodies and protein A beads for 1 h at 4ЊC. The pellets were washed four times with lysis buffer and separated on a sodium dodecyl sulfate (SDS)-15% polyacrylamide gel. For Western blot (immunoblot) analyses, 40 g of each cell lysate was separated on an SDS-polyacrylamide gel and transferred to nylon membranes (Millipore). The membranes were blocked in blocking buffer (1ϫ PBS, 0.2% Tween 20, 5% dry milk) and incubated with the primary antibodies in Western buffer (1ϫ PBS, 0.2% Tween 20, 2% dry milk) for 1 h at room temperature. Dilutions of primary antibodies were 1:100, except anti-cyclin E antiserum, which was diluted at 1:500. After three washes with Western buffer, the blots were incubated with secondary antibodies (goat anti-rabbit, goat anti-mouse, and goat anti-rat [Amersham] ) and developed by using the ECL chemiluminescence reagent (Amersham). Additional antibodies for the Western blot analyses included a purified polyclonal antibody against the C terminus of p34cdc2 (GIBCO BRL). Also used was a purified rabbit polyclonal antibody to cyclin A (Santa Cruz Biotechnology). Immunoblots were performed with the anti-p21 C terminus antibody from Santa Cruz Biotechnology. Anti-cyclin E antibody was a gift from H. Kiyokawa (16) . cdk assays. Cell extracts for the kinase assays were prepared by washing the cells twice with 1ϫ PBS, resuspending them in lysis buffer (50 mM Tris [pH 7.6], 250 mM NaCl, 0.1% NP-40, 2 g of leupeptin per ml, 2 g of aprotinin per ml, 1 mM phenylmethylsulfonyl fluoride), and lysing them by passage through G21 needles (32) . The cell lysates were cleared of insoluble materials by centrifugation at 12,000 ϫ g and used immediately or stored at Ϫ80ЊC. The protein concentrations of the lysates were determined by the Bradford method (BioRad). After being precleaned with protein A-agarose beads (Boehringer Mannheim), the extracts were immunoprecipitated with either anti-cdk2 or p13-agarose beads (Oncogene Science), and the pellets were washed twice in lysis buffer and then three times in kinase buffer (50 mM Tris [pH 8.0], 10 mM MgCl 2 , 1mM dithiothreitol, 2 g of leupeptin per ml, 2 g of aprotinin per ml, 1 mM phenylmethylsulfonyl fluoride) and incubated in 50 l of kinase assay solution (100 g of histone H1 per ml, 10 M ATP, 4 Ci of [␥-
32 P]ATP, in kinase buffer) for 20 min at room temperature. The reactions were terminated by the addition of 20 l of SDS sample buffer and the mixtures were boiled for 5 min. Half of the volumes were loaded onto an SDS-12% polyacrylamide gel and exposed to Kodak X-ray film following electrophoresis.
Northern (RNA) blot analyses. Northern blot analysis was performed with 20 g of total RNA prepared by using RNAzol B (Biotecx Laboratories, Inc.). After transfer to a Hybond-N membrane (Amersham) and UV cross-linking, the blot was hybridized with murine p21 (6) or MyoD cDNA (2) probes generated by random primer labeling (Boehringer Mannheim), according to the manufacturer's instructions. The DNA template for p21 was generated by PCR with template DNA prepared from a mouse C2C12 myotube cDNA library. Sequences for the PCR primers were 5Ј-TGTTTCAGCCACAGGCACC-3Ј (forward) and 5Ј-CTCTGCTCCTGTCCTTACC-3Ј (reverse). After hybridization, the blots were washed for 20 min at 65ЊC in 0.2ϫ SSC (1ϫ SSC is 0.15 M NaCl plus 0.015 M sodium citrate)-0.1% SDS and exposed to Kodak X-ray film. Growth arrest assays. Proliferation assays were conducted by using the ␤-galactosidase cotransfection method of Simonson et al. (31) . C2C12 cells were plated at low density on 6-well plates in DMEM containing 20% FBS. Cells were transfected by utilizing calcium phosphate with pMSV-LacZ (3.3 g per well) and 6.6 g of either pCEP-WAF1-S (expressing sense mRNA for p21) or pCEP-WAF1-AS (expressing antisense mRNA for p21) per well (6) . Transformed cells were incubated for 24 h to allow expression of plasmid-encoded genes, and then proliferating cells were labeled with 20 M 5-bromo-2Ј-deoxyuridine (BrdU) for 24 h in 20% FBS-containing medium. The cells were fixed and then stained for ␤-galactosidase activity with Red-Gal (Research Organics, Inc.), while proliferating cells were stained for BrdU incorporation with diaminobenzidine by using a mouse anti-BrdU antibody (Boehringer Mannheim) and a Histomark streptavidin-horseradish peroxidase system (Kirkegaard & Perry Laboratories).
RESULTS
To assay for changes in cdk activity during myocyte terminal differentiation, C2C12 myoblast and myotube extracts were precipitated with anti-cdk2 antibodies or with agarose-conjugated p13, a yeast protein which has been shown to bind a variety of cdk's (3). Comparing the abilities of these precipitated extracts to phosphorylate histone H1 revealed a dramatic reduction in cdk activity in the mitogen-depleted myotube cultures relative to the myoblast cultures, which could not be restored upon stimulation of the myotubes for 24 h with mitogen-rich growth medium (Fig. 1) . This irreversible reduction in cdk activity is consistent with the observation that the myocyte differentiation process is irreversible, and myotubes reexposed to growth medium cannot reactivate their DNA synthesis program (29) .
The expression levels of cdc2 and cdk2 and of two of their cyclin subunits, cyclin A and cyclin E, were analyzed during myogenesis by Western blot analyses. The induction of C2C12 cell differentiation by mitogen deprivation led to decreases in the expression of cdc2, cdk2, and cyclin A, but the level of cyclin E protein did not detectably change (Fig. 2) . The stimulation of myotube cultures with high-mitogen medium led to (13, 27, 36) . Collectively, these data suggest that while the levels of some cdk's and cyclins are downregulated upon myocyte differentiation, myotubes contain substantial levels of some of these factors, and they also suggest that the stimulation of myotubes with mitogens can partially restore some cell cycle proteins to the levels found in the replicating myoblast cultures. Extract-mixing experiments were performed to test whether the induction of an inhibitory activity upon myogenesis may contribute to the decrease in cdk activity in myotubes (Fig.  3A) . In these experiments, extracts were heat treated to eliminate cdk activity and then mixed with untreated myoblast extracts in the histone kinase reaction with the cdk2 immunoprecipitates. A heat-stable cdk inhibitory activity could be detected in the myotube extracts, but not in the heat-treated myoblast extracts, and the inhibitory activity was maintained in myotubes following restimulation with growth medium.
Clues as to the nature of the induced cdk inhibitory activity were revealed when 35 S-labeled anti-cdk2 and anti-cdk4 immunoprecipitates displayed an associated protein band at ϳ21 kDa that was highly expressed in myotubes but not in myoblasts (data not shown). To test whether this cdk-associated protein was the p21 cdk inhibitor, Western blot analyses with anti-p21 antibodies were performed with the immunoprecipitated complexes (Fig. 4A) . A 21-kDa band was detected in immunoblots of extracts that were immunoprecipitated with anti-cdk4, anti-cdk2, and anti-p21 antibodies but not in extracts that were immunoprecipitated with a control antibody (␣-gax). This band was detected at higher levels in myotube extracts than in myoblast extracts, and it was not detected when the immunogenic p21 peptide was preincubated with the anti-p21 antibody prior to the immunoprecipitation step. Direct Western blot analysis with myocyte extract proteins revealed that p21 was strongly induced upon differentiation, and its expression persisted when myotube cultures were reexposed to highmitogen growth medium (Fig. 4B) . Further, indirect immunofluorescence microscopy demonstrated that myosin heavychain-positive myotubes expressed p21 in their nuclei (data not shown). Collectively, these data indicate that p21 protein levels are markedly upregulated during C2C12 terminal differentiation.
To determine the extent to which p21 contributed to the heat-stable cdk inhibitory activity induced in myotubes, the extracts were immunodepleted with anti-p21 antibodies and assayed for their cdk2 inhibitory activity (Fig. 3) . Myotube and mitogen-stimulated myotube extracts depleted in this fashion were ineffective at inhibiting the cyclin kinase activity from myoblasts, whereas immunodepletion with control anti-Sp1 antibodies had no effect on the inhibitory activity from myotubes. Similar results were obtained whether myotube extracts were immunodepleted with anti-p21 antibodies raised to a recombinant fusion protein (Fig. 3A) or to p21 peptides (Fig. 3B ) that were chosen because they do not share homology with the p27 cdk inhibitor. An excess of immunogenic p21 peptide could prevent the corresponding antibody from removing the cdk inhibitory activity, further demonstrating the specificity of the immunodepletion reaction. In contrast, anti-p27 peptide antibodies did not specifically immunodeplete the cdk inhibitory activity that was induced upon myogenesis. As an additional control, the treatment of heat-inactivated myoblast extracts with anti-p21 antibodies had no effect on the kinase reaction (Fig. 3A) . Though we cannot rule out the participation of other cdk inhibitors, these data indicate that p21 contributes to the reduction of cdk activity during the differentiation of myoblasts to myotubes.
We next expressed p21 in growing myoblast cultures to assess the potential significance of its upregulation during myogenesis (31) . The expression vector with p21 cDNA in the sense orientation (pCEP-WAF1-S) significantly decreased the percentage of myoblasts in S phase, but a control vector with p21 cDNA in the antisense orientation (pCEP-WAF1-AS) had no detectable effect on cell growth (Table 1) . These data are consistent with previous reports that p21 can inhibit the proliferation of fibroblasts and human tumor cells (6, 12, 22) , and   FIG. 3 . Anti-p21 antibodies can deplete the cdk inhibitory activity that is induced upon myogenesis. (A) Extracts (12 g) from myotubes (Mt), myotubes reexposed to serum for 12 h (SSMt), or myoblasts (Mb) were boiled for 10 min, cleared of insoluble materials by centrifugation, and mixed with 2 g of myoblast extract at 4ЊC for 1 h by rotating. After immunoprecipitation with anti-cdk2 antibodies, histone H1 kinase activity was assayed. For anti-p21 (␣-p21) or anti-Sp1 (␣-Sp1) (control) depletion assays, 12 g of the cleared extract was precleaned with protein A-agarose and incubated with 2 g of antibody raised against the recombinant fusion protein. This mixture was immunoprecipitated, and the supernatant was mixed with 2 g of the myoblast extract to determine histone H1 kinase activity as outlined above. (B) Immunodepletion by anti-p21 (␣-p21) peptide antibodies. Kinase reactions were performed as described for panel A by using boiled myotube extract as a source of inhibitory activity. Immunodepletion experiments were performed with 1 g of antibody in the presence or in the absence of a molar excess (1 g) of the corresponding immunogenic peptide. Activity is expressed relative to the ''ϩ peptide'' condition to display specific immunodepletion. The anti-peptide antibodies were from Santa Cruz Biotechnology, and their catalog numbers are indicated. The anti-p27 (␣-p27) antibody was raised against a peptide that does not share homology with p21.
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on February 21, 2013 by PENN STATE UNIV http://mcb.asm.org/ they demonstrate that ectopic expression of p21 in myoblasts is sufficient to inhibit cell cycle progression despite the presence of the mitogen-rich growth medium. Northern blot analyses were performed with C2C12 cultures to further characterize the upregulation of p21 during myocyte terminal differentiation. The level of p21 mRNA was low or nondetectable in growing myoblast cultures, but significant levels of expression could be detected at 24 to 48 h following the shift to differentiation medium (Fig. 5A) , when myotubes were evident by visual examination. In a separate experiment, myogenin, which is absent in C2C12 myoblasts but upregulated during myogenesis (5), exhibited a similar time course of induction (data not shown). The level of p21 mRNA expression following 48 h in differentiation medium was comparable to that in cultures of myotubes treated with ara-cytosine to eliminate myoblasts (Fig. 5B) . Furthermore, p21 mRNA expression in myotube cultures was not detectably diminished following reexposure to mitogen-rich growth medium. These data demonstrate that despite the fact that myogenesis is initiated by mitogen deprivation, p21 expression becomes uncoupled from mitogen levels in the myotube. These findings suggest that permanent changes in the myocyte's genetic program are involved in the induction and maintenance of p21 expression upon terminal differentiation.
These results offer compelling but indirect evidence that p21 upregulation is an integral feature of C2C12 terminal differentiation rather than the simple consequence of growth factor deprivation. To directly assess the effects of the myogenic factors on p21 upregulation, we established a 10T1/2 cell line that was stably transformed with a MyoD expression vector (39) . These MyoD-transformed cells, unlike the parental 10T1/2 cells, expressed endogenous MyoD and formed multinucleated myotubes that expressed myosin heavy-chain when exposed to mitogen-poor differentiation medium (Fig. 6A) . Differentiating 10T1/2-MyoD cells dramatically upregulated the expression of p21 (Fig. 6B) and myogenin (not shown), which did not occur in the parental 10T1/2 fibroblasts when exposed to the differentiation medium. These data demonstrate that the upregulation of p21 expression requires muscle cell commitment and differentiation and that its expression is activated, directly or indirectly, by the myogenic bHLH factors.
DISCUSSION
Our results show that p21 upregulation is an integral feature of myogenic commitment and differentiation. We demonstrate that p21 is induced at the levels of mRNA and protein and that anti-p21 antibodies can specifically immunodeplete the heat- and 80% confluence at the time of harvest and from cells exposed to differentiation medium for the indicated times. (B) Myotubes do not downregulate p21 transcript levels when exposed to serum mitogens. Myotubes were prepared by exposure to differentiation medium for 2 days, and then 10 M ara-cytosine was added for an additional 2 days (Mt lane). Myotubes were exposed to 20% FBS in DMEM for the indicated times after ara-cytosine treatment. Q48 refers to myoblasts exposed to differentiation medium for 2 days (no ara-cytosine treatment). a Proliferating C2C12 myoblasts were transfected with pMSV-␤-gal, which expresses ␤-galactosidase, and either pCEP-WAF1-S, which expresses the p21 gene in the sense orientation, or pCEP-WAF1-AS, which has the p21 gene in the antisense orientation. Transfected cells expressing ␤-galactosidase were scored positive for BrdU incorporation and DNA synthesis. stable cdk inhibitory activity that is induced upon myogenesis. Further, p21 complexes with cdk's were detected in myotubes. On the basis of this evidence and the observation that ectopic expression of p21 in growing myoblasts is sufficient to inhibit cell cycle progression, we propose that the induction and sustained expression of p21 have an important role in coupling irreversible withdrawal from the cell cycle with phenotypic differentiation during myogenesis. Following the submission of the manuscript it was reported that MyoD induced p21 expression in vitro (10, 25) . These reports are in general agreement with the data reported here, and they are consistent with the hypothesis that the decrease in cdk activity observed during myogenesis partially results from the interaction of p21 with the cyclin-cdk complexes, thereby contributing to the establishment and maintenance of the postmitotic state of myotubes.
Both MyoD and serum deprivation are required for the induction of p21 (Fig. 7) . The p21 levels are low in proliferating cells, and serum withdrawal is not sufficient to induce its expression in uncommitted 10T1/2 cells, which do not express MyoD. However, p21 is dramatically upregulated upon terminal differentiation of cells committed to the myogenic program. The inability of MyoD to induce p21 expression in proliferating myogenic cells might be due, at least in part, to inactivation of MyoD through heterodimerization with Id, a dominant-negative HLH protein expressed at high levels in proliferating cells and downregulated upon serum withdrawal (1) . For this same reason, endogenous MyoD is not transactivated by the virally encoded MyoD in the high-mitogen growth medium (Fig. 6B) .
It has long been known that the mitogen stimulation of levels of some cell cycle components, including cdk2 and cyclin E (Fig. 2) , as well as the Rb kinases, cdk4 and cdk6, and their cyclin subunits (37) . Further, this regulation is in some cases reversible, since the levels of some, but not all, cdk's and cyclins can be partially restored to their myoblast levels by exposing myotube cultures to a high-mitogen medium (e.g., cdk2 and cyclin A). In contrast, p21 is markedly upregulated during myogenesis, and the levels of p21 protein, mRNA, and cdk inhibitory activity remain high when myotube cultures are stimulated by mitogens. Analyses of the mechanism of p21 upregulation during myogenesis will be of interest because they should provide insight into how the cell cycle is coordinated with the expression of the differentiated phenotype. p21 is upregulated by many environmental stimuli, including ␥-irradiation (4, 6), cytotoxic and cytostatic agents (15) , and, in some cases, serum stimulation (20) . Details of this regulation are understood only for ␥-irradiation, in which case DNA damage induces p53 which, in turn, activates p21 transcription by binding to cis regulatory elements in the p21 promoter (6) . However, p53-independent regulation of p21 expression has been demonstrated in a number of other systems (14, 15, 20, 33) . It is possible that myogenic bHLH or MEF2 factors directly activate p21 transcription in a manner similar to the activation of contractile protein genes. C2C12 myocytes transiently or stably transfected with constructs containing 2.4-or 4.5-kbp promoter fragments of the p21 gene displayed high levels of activity in myoblast and myotube cultures but did not confer significant differentiationdependent upregulation of reporter gene expression, suggesting that outlying regions may be required for proper regulation (9) . Unlike muscle-specific contractile protein genes, p21 transcripts are widely expressed in adult human tissues-lung, liver, kidney, pancreas, and placenta, in addition to skeletal and cardiac muscle (7, 8, 25) . Further, it has also been reported that differentiation-inducing agents can upregulate p21 expression in hematopoietic and hepatoma cell lines (14, 33) . These observations suggest that the ubiquitous upregulation of p21 may involve a common differentiation-specific regulatory mechanism that functions in diverse cell types. Finally, it will be of interest to analyze p21 regulation in cells that display a differentiated phenotype but do not undergo permanent growth arrest, as occurs with smooth muscle cells, which can dedifferentiate and reenter the cell cycle in response to growth factor stimulation. These comparisons may provide insights about the general mechanisms by which cells irreversibly exit the cell cycle as part of their terminal differentiation program.
